Unresectable, locally advanced HR Positive, HER2/Neu Negative Breast Cancer

Drug	Drug Name	Drug Description
DB12893	Sacituzumab govitecan	Sacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis.

Drug	Drug Name	Target	Type
DB12893	Sacituzumab govitecan	Tumor-associated calcium signal transducer 2	target
DB12893	Sacituzumab govitecan	DNA topoisomerase 1	target
DB12893	Sacituzumab govitecan	Far upstream element-binding protein 1	target
DB12893	Sacituzumab govitecan	UDP-glucuronosyltransferase 1-1	enzyme

Drug	Drug Name	Phase	Status	Count